15. Aspects to Consider When Low-Level Active Pharmaceutical Ingredient/Drug Product Degradants have the Potential for Genotoxicity

  1. Andrew Teasdale
  1. Alan P. McKeown1 and
  2. Andrew Teasdale2

Published Online: 3 JAN 2011

DOI: 10.1002/9780470929377.ch15

Genotoxic Impurities

Genotoxic Impurities

How to Cite

McKeown, A. P. and Teasdale, A. (2011) Aspects to Consider When Low-Level Active Pharmaceutical Ingredient/Drug Product Degradants have the Potential for Genotoxicity, in Genotoxic Impurities (ed A. Teasdale), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470929377.ch15

Editor Information

  1. AstraZeneca, Leicester, United Kingdom

Author Information

  1. 1

    Pfizer, Kent, United Kingdom

  2. 2

    AstraZeneca, Leicester, United Kingdom

Publication History

  1. Published Online: 3 JAN 2011
  2. Published Print: 14 FEB 2011

ISBN Information

Print ISBN: 9780470499191

Online ISBN: 9780470929377

SEARCH

Options for accessing this content:

  • If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
    http://wiley.force.com/Interface/ContactJournalCustomerServices_V2.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Chapter for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens

or

Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >